Skip to main content
Clinical Trials/NCT02112825
NCT02112825
Completed
Not Applicable

Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease

University of Minnesota1 site in 1 country40 target enrollmentJuly 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Focus Chronic Kidney Disease With Hypertension
Sponsor
University of Minnesota
Enrollment
40
Locations
1
Primary Endpoint
blood pressure
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The general objective of the study is to investigate the effect of regular aerobic exercise on resting and 24-hr blood pressure levels in men and women with stage 3-4 kidney disease and hypertension.

Registry
clinicaltrials.gov
Start Date
July 2013
End Date
June 2015
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • • Non-diabetic and \>18 years of age
  • Diagnosed kidney disease with associated hypertension:
  • Non-nephrotic range proteinuria at diagnosis
  • No active glomerular disease or concomitant systemic inflammatory disease (e.g. lupus)
  • Systolic blood pressure \>130 and/or diastolic blood pressure \>80 mm Hg (on medication)
  • An estimated glomerular filtration rate of between 60 ml/min and 15 ml/min.
  • Individuals must be able to provide informed consent
  • Perform walking exercise training on a treadmill
  • Be able to participate in a 12-week supervised exercise program.

Exclusion Criteria

  • Currently participating in a formal exercise program
  • Diabetes, active glomerular disease, or systemic inflammatory disease
  • Requiring dialysis
  • Have an Hematocrit \<27%
  • Uncontrolled hypertension (\>200/110mmHg)
  • Peripheral vascular disease.
  • An inability to understand English or give consent. Other exclusion criteria are: any contraindications to exercise testing or training as indicated by the American College of Sports Medicine guidelines such as: Unstable coronary heart disease and symptomatic heart failure, exercise capacity limited by health problems such as angina, severe arthritis, or extreme dyspnea on exertion, progressive neuromuscular disease, pulmonary disease, or having undergone a coronary revascularization within the past 6 months prior to enrollment.

Outcomes

Primary Outcomes

blood pressure

Time Frame: at week 0 and at week 12

resting and 24-hour ambulatory blood pressure

Secondary Outcomes

  • effective vascular compliance(at week 0 and at week 12)
  • endothelial function(at week 0 and at week 12)
  • biomarkers associated with blood pressure(at week 0 and at week 12)

Study Sites (1)

Loading locations...

Similar Trials